COMMUNIQUÉ DE PRESSE
News
-
-
-
-
COMMUNIQUÉ DE PRESSE
Jaguar Health Celebrates National Service Dog Month: With its Supportive Cancer Care Drugs, Jaguar is Dedicated to the Health and Wellbeing of People and Dogs
Jaguar Health's Canalevia-CA1 drug receives FDA conditional approval for chemotherapy-induced diarrhea treatment in dogs, making it the first approved treatment for this condition -
-
-
COMMUNIQUÉ DE PRESSE
New Innovators with Jane King Interview with Jaguar Health CEO Lisa Conte Spotlights Company’s Near-Term Commercial & Development Milestones
Jaguar Health, Inc. announces near-term activities including Gelclair launch and crofelemer trials for rare diseases. Includes Lisa Conte interview details -
-
-
COMMUNIQUÉ DE PRESSE
Patent Issued in Jordan Bolsters IP Protection for Jaguar Health in the Treatment of Short Bowel Syndrome (SBS)
Jaguar Health, Inc. announces issuance of new patent for crofelemer to treat rare diseases like SBS and MVID, enhancing IP protection. Independent studies supported in US, EU, and MENA regions
